Nuvalent Inc (NUVL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvalent Inc (NUVL) has a cash flow conversion efficiency ratio of -0.079x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.40 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Nuvalent Inc market cap and net worth for the company's overall valuation and market capitalisation.
Nuvalent Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Nuvalent Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nuvalent Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvalent Inc ranked by their cash flow conversion efficiency. Explore Nuvalent Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pentair PLC
NYSE:PNR
|
-0.018x |
|
Ryder System Inc
NYSE:R
|
0.236x |
|
Hotai Motor Co Ltd
TW:2207
|
0.112x |
|
China XD Electric Co Ltd
SHG:601179
|
0.023x |
|
The Federal Bank Limited
NSE:FEDERALBNK
|
-0.058x |
|
Indra A
MC:IDR
|
0.004x |
|
Menora Miv Hld
TA:MMHD
|
0.011x |
|
Ayvens SA
PA:AYV
|
0.459x |
Annual Cash Flow Conversion Efficiency for Nuvalent Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Nuvalent Inc from 2019 to 2025. View Nuvalent Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.25 Billion | $-275.21 Million | -0.220x | -27.44% |
| 2024-12-31 | $1.07 Billion | $-185.06 Million | -0.173x | -21.51% |
| 2023-12-31 | $700.56 Million | $-99.74 Million | -0.142x | -1.45% |
| 2022-12-31 | $462.98 Million | $-64.97 Million | -0.140x | 0.00% |
| 2021-12-31 | $285.04 Million | $-40.00 Million | -0.140x | -129.40% |
| 2020-12-31 | $-31.32 Million | $-14.95 Million | 0.477x | -14.56% |
| 2019-12-31 | $-17.26 Million | $-9.64 Million | 0.559x | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more